Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients?

Fabio Castiglione; Alessandro Nini; Alberto Briganti

doi:10.1016/j.eururo.2013.11.049

Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients?

Eur Urol. 2014 Apr;65(4):673-4. doi: 10.1016/j.eururo.2013.11.049. Epub 2013 Dec 25.

Authors

Fabio Castiglione¹, Alessandro Nini¹, Alberto Briganti²

Affiliations

¹ San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy.
² San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy. Electronic address: [email protected].

PMID: 24388439
DOI: 10.1016/j.eururo.2013.11.049

Abstract

The results reported in all trials comparing chronic versus on-demand phosphodiesterase type 5 inhibitor use after bilateral nerve-sparing radical prostatectomy may be affected by improper patient selection. Targeting the right patients is the key to optimizing the efficacy of these drugs.

Publication types

Editorial

MeSH terms

Erectile Dysfunction / drug therapy*
Erectile Dysfunction / rehabilitation*
Humans
Male
Organ Sparing Treatments
Patient Selection
Penis / innervation
Phosphodiesterase 5 Inhibitors / therapeutic use*
Prostatectomy / adverse effects*
Prostatectomy / methods*

Substances

Phosphodiesterase 5 Inhibitors